By demonstrating the most dramatic reversal of amyloid deposition in an Alzheimer’s disease mouse model to date, a new study gives renewed support to the BACE1 inhibitor class in human trials.
Volumetric analysis of brain MRI allows for accurate and prompt rendering of the cortical surface. Here’s how we’re using it in three common neurological diseases.
Five million Americans currently have Alzheimer’s disease (AD); left unchecked, that number will balloon to 16 million by 2050. Given the debilitating nature of the disease, research has turned its focus to the prevention and early treatment of cognitive and behavioral symptoms.
A large NIH grant has helped form the first national research consortium for this common neurodegenerative dementia. The search for biomarkers is high on its to-do list.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Under a collaboration with the NFL Players Association, over 400 former players have had brain-body health evaluations at Cleveland Clinic to get a sense of the brain health path they appear to be on. Here’s how it works.
The PRIME study of the immunotherapy agent aducanumab for Alzheimer’s disease made big news recently. An investigator in ongoing phase 3 trials of the agent sizes up PRIME and looks to what’s next.
An expert panel at Cleveland Clinic’s recent Medical Innovation Summit explained why much earlier intervention will be key to success in AD therapeutics — and how biomarkers and big data will help us get there.
Alzheimer disease, Parkinson disease, normal aging and neuroinflammation are priority focus areas of the biobank, which aim to promote identification of novel biomarkers. The facility will benefit from Cleveland Clinic’s large, diverse patient population and neuroinflammation research expertise.